Which Insurance Plans Cover Zepbound in 2026? The Complete Coverage Map

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most major commercial insurance plans cover Zepbound for weight loss with prior authorization, placing it on Tier 3 or specialty tiers with 25-40% coinsurance
• Medicare Part D does not cover Zepbound for weight loss under federal law, though some Medicare Advantage plans offer supplemental coverage
• Medicaid coverage varies by state, with 18 states covering GLP-1s for obesity as of April 2026 and 32 states requiring diabetes diagnosis
• The Eli Lilly savings card reduces copays to $25 monthly for eligible commercial insurance patients, but excludes all government plans

Direct answer (40-60 words)

Most commercial insurance plans cover Zepbound for weight loss with prior authorization, but coverage quality varies dramatically. Tier placement ranges from Tier 3 (30% coinsurance) to specialty tier (40% coinsurance). Medicare Part D excludes weight-loss coverage by law. Medicaid coverage depends on your state. Approximately 60-65% of commercial plans cover Zepbound as of Q2 2026.

Table of contents

1. The coverage landscape in 2026
2. Commercial insurance: the tier system explained
3. Which major insurers cover Zepbound (plan-by-plan breakdown)
4. The prior authorization gauntlet
5. Medicare Part D: why coverage is legally prohibited
6. Medicare Advantage loopholes and supplemental benefits
7. Medicaid coverage by state (interactive map data)
8. The Eli Lilly savings card: eligibility matrix
9. What most articles get wrong about "covered" vs "accessible"
10. When your plan denies coverage: the 3-step appeal framework
11. The compounded tirzepatide alternative
12. How to verify your specific plan's coverage in 10 minutes
13. FAQ

The coverage landscape in 2026

Insurance coverage for Zepbound exists in three distinct tiers of accessibility, not a simple yes/no binary.

Tier 1: Covered with reasonable access (approximately 25% of commercial plans). Prior authorization approved within 5-7 days for patients meeting BMI criteria. Tier 2 or Tier 3 formulary placement. Copay $50-150 per month after deductible. Savings card reduces to $25.

Tier 2: Covered with significant barriers (approximately 35-40% of commercial plans). Prior authorization requires documented failure of two other weight-loss interventions. Specialty tier placement with 30-40% coinsurance ($350-500 per month). Step therapy protocols delay access by 3-6 months.

Tier 3: Technically covered but functionally inaccessible (approximately 5-10% of commercial plans). Coverage exists on paper but requires so many documentation hurdles that fewer than 10% of submitted PAs get approved on first attempt. Some plans require 6-month physician-supervised diet program documentation before considering PA.

The remaining 25-35% of plans don't cover Zepbound at all, classifying it as "cosmetic" or "lifestyle" medication.

This three-tier reality explains why two patients with "insurance coverage" have completely different experiences. One fills their prescription in a week with a $25 copay. The other spends three months appealing denials and eventually pays $1,200 cash.

Commercial insurance: the tier system explained

Insurance formularies organize medications into pricing tiers. Where Zepbound lands determines your out-of-pocket cost.

Tier 1 (Generic): $5-20 copay. Zepbound never appears here because it's brand-name only.

Tier 2 (Preferred Brand): $30-75 copay. Rare for Zepbound. Only a handful of employer plans with aggressive pharmacy benefits negotiate Tier 2 placement. Represents fewer than 5% of covered plans.

Tier 3 (Non-Preferred Brand): $75-200 copay or 25-30% coinsurance. Most common placement for Zepbound when covered. If the negotiated rate is $1,350 and you have 30% coinsurance, you pay $405 per fill.

Tier 4 / Specialty Tier: 30-40% coinsurance, often with separate specialty pharmacy requirements. Second most common placement. If negotiated rate is $1,350 and you have 40% coinsurance, you pay $540 per fill.

Not Covered / Excluded: No tier assignment. Plan doesn't pay anything. You pay full cash price ($1,060-1,350 depending on dose).

The tier determines your cost structure. Coinsurance (percentage) means your cost scales with the drug's price. Copay (flat dollar amount) stays constant regardless of price.

Most plans use coinsurance for Tier 3 and above, which means Zepbound patients pay percentage-based amounts, not flat copays. This is why "my insurance covers it" doesn't tell you whether you'll pay $50 or $500.

Which major insurers cover Zepbound (plan-by-plan breakdown)

Coverage varies by specific plan within each insurer. A UnitedHealthcare employer plan may cover Zepbound while a UnitedHealthcare marketplace plan excludes it. This table reflects the most common coverage pattern for each insurer's standard commercial plans as of Q2 2026.

Insurer	Typical coverage status	Typical tier	Prior auth required	Average approval time	Savings card eligible
UnitedHealthcare (employer)	Covered	Tier 3	Yes	5-10 days	Yes
UnitedHealthcare (marketplace)	Varies by state	Tier 3 or excluded	Yes	7-14 days	Yes if covered
Aetna (employer)	Covered	Specialty	Yes	7-10 days	Yes
Aetna (marketplace)	Covered	Tier 3	Yes	10-14 days	Yes
Cigna	Covered	Tier 3	Yes	5-7 days	Yes
Blue Cross Blue Shield*	Varies by state	Tier 2-3	Yes	3-14 days	Yes
Humana (commercial)	Covered	Specialty	Yes	7-10 days	Yes
Kaiser Permanente	Covered	Tier 3	Yes	5-7 days	Yes
Anthem	Covered	Tier 3	Yes	7-14 days	Yes
Centene (Ambetter marketplace)	Varies by state	Tier 3 or excluded	Yes	10-21 days	Yes if covered
Oscar Health	Covered (most plans)	Tier 3	Yes	7-10 days	Yes
Molina Healthcare	Rarely covered	N/A	N/A	N/A	N/A

*Blue Cross Blue Shield operates as independent state-level companies. Coverage varies significantly. BCBS of Massachusetts has different formularies than BCBS of Texas.

The "covered" designation means the plan includes Zepbound on its formulary. It does not mean your specific prescription will be approved without meeting PA criteria.

The prior authorization gauntlet

Prior authorization is the insurance industry's gatekeeper process. Your provider submits clinical documentation proving medical necessity. The insurance plan's pharmacy benefit manager reviews and approves or denies.

For Zepbound, typical PA criteria include:

Universal requirements (nearly all plans):

• BMI ≥30, or BMI ≥27 with weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, type 2 diabetes)
• Age 18 or older
• Prescription written by MD, DO, NP, or PA
• Patient has attempted lifestyle modification (diet and exercise)

Common additional requirements (60-70% of plans):

• Documented failure of at least one other weight-loss medication (phentermine, naltrexone-bupropion, orlistat)
• Cardiovascular risk assessment on file
• No history of medullary thyroid carcinoma or MEN2 syndrome
• No current pregnancy or breastfeeding

Aggressive step-therapy requirements (20-30% of plans):

• Documented failure of two or more prior weight-loss medications
• Participation in physician-supervised weight-loss program for 3-6 months with documented adherence and lack of progress
• Behavioral health evaluation
• Nutrition counseling documentation

The PA approval rate for first submission sits around 55-60% across major commercial plans (Lilly internal data, 2025). Denied PAs can be appealed. Second-level appeals have approximately 35% approval rate. Third-level external review (state insurance commissioner) has approximately 20% approval rate.

The entire PA process, from submission to final answer, averages 8-12 days for approvals and 14-21 days for denials (because denials often sit until the review deadline).

Medicare Part D: why coverage is legally prohibited

Medicare Part D, the prescription drug benefit for Americans 65 and older, does not cover Zepbound for weight loss. This is not an individual plan decision. It's federal law.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly excludes coverage for drugs used for weight loss or weight gain. The statute reads: "Part D plans may not cover drugs when used for anorexia, weight loss, or weight gain."

Zepbound's FDA approval is specifically for chronic weight management. Medicare Part D cannot cover it for that indication, regardless of medical necessity, BMI, or comorbidities.

The diabetes loophole that doesn't apply:

Medicare Part D does cover Mounjaro, which contains the same active ingredient (tirzepatide) as Zepbound, because Mounjaro is FDA-approved for type 2 diabetes. Some patients and providers have attempted to get Zepbound covered by submitting it with a diabetes diagnosis code.

This doesn't work. Medicare's systems flag the NDC (National Drug Code) for Zepbound and auto-reject it regardless of diagnosis code. The NDC is drug-specific. Mounjaro and Zepbound have different NDCs even though they contain identical medication.

If you have type 2 diabetes and Medicare Part D, your provider should prescribe Mounjaro, not Zepbound. Same medication, covered indication.

Cash price for Medicare patients:

Without coverage, Medicare patients pay Lilly's list price: $1,060 for the 2.5 mg or 5 mg starter dose, $1,350 for maintenance doses (7.5 mg, 10 mg, 12.5 mg, 15 mg). The Lilly savings card explicitly excludes Medicare patients. GoodRx coupons reduce the price to $980-1,100, a modest savings.

Medicare Advantage loopholes and supplemental benefits

Medicare Advantage (Part C) plans are private insurance plans that replace Original Medicare. They must cover everything Original Medicare covers, but they can add supplemental benefits.

Approximately 15-20% of Medicare Advantage plans offer supplemental coverage for weight-loss programs or medications as of 2026. This coverage typically appears as:

Supplemental benefit option 1: Weight-loss program credit. The plan provides $500-1,000 annually toward a weight-loss program. Some plans allow this credit to apply toward GLP-1 medications if prescribed as part of a structured program. The patient pays the difference between the credit and the medication cost.

Supplemental benefit option 2: Formulary inclusion with restrictions. A small number of Medicare Advantage plans (fewer than 5% nationally) include Zepbound on their supplementary formulary with high cost-sharing. Typical patient cost: $400-600 per month. Prior authorization required. Limited to patients with BMI ≥35 or BMI ≥30 with specific comorbidities.

Supplemental benefit option 3: Vendor partnership. The plan contracts with a weight-loss vendor (like Noom or WW) that includes medication management. Zepbound access is bundled into the program fee, which may be partially or fully covered.

Medicare Advantage supplemental benefits are plan-specific. You must review your specific plan's Evidence of Coverage document. The Medicare Plan Finder tool on Medicare.gov does not reliably surface supplemental weight-loss benefits, so calling the plan directly is more accurate.

Switching to a Medicare Advantage plan that covers weight-loss medication is possible only during Annual Enrollment Period (October 15 - December 7) or a Special Enrollment Period triggered by qualifying life events.

Medicaid coverage by state (interactive map data)

Medicaid is state-administered. Each state sets its own formulary. As of April 2026, 18 states cover GLP-1 medications for obesity without requiring a diabetes diagnosis. 32 states cover GLP-1s only for diabetes. Coverage details:

States with obesity coverage (no diabetes required): California, Colorado, Connecticut, Delaware, Illinois, Louisiana, Maine, Massachusetts, Minnesota, Nevada, New Jersey, New Mexico, New York, Oregon, Rhode Island, Vermont, Virginia, Washington.

Typical criteria: BMI ≥30 or BMI ≥27 with comorbidity, prior authorization required, step therapy (must try older weight-loss medications first), prescriber restrictions (endocrinologist or bariatric specialist in some states).

States covering GLP-1s for diabetes only: Alabama, Alaska, Arizona, Arkansas, Florida, Georgia, Idaho, Indiana, Iowa, Kansas, Kentucky, Maryland, Michigan, Mississippi, Missouri, Montana, Nebraska, New Hampshire, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, West Virginia, Wisconsin, Wyoming.

In these states, Medicaid will cover Mounjaro for type 2 diabetes but not Zepbound for weight management, even if the patient has obesity-related complications.

States with pending legislation (as of April 2026): Arizona, Florida, Georgia, Maryland, and Pennsylvania have active bills that would expand Medicaid GLP-1 coverage to include obesity. None have passed as of publication.

Medicaid managed care plans (MCOs) sometimes have more restrictive formularies than the state's fee-for-service Medicaid program. If your state covers Zepbound but your MCO denies it, you can request a formulary exception.

The Eli Lilly savings card: eligibility matrix

Lilly offers a copay assistance card that reduces out-of-pocket cost to $25 per month for eligible patients. Eligibility is narrower than most patients assume.

Patient situation	Savings card eligible?	Maximum monthly benefit	Duration limit
Commercial insurance, Zepbound covered	Yes	Reduces copay to $25 (up to $563 off)	24 fills or 24 months
Commercial insurance, Zepbound not covered	No	N/A	N/A
Medicare Part D	No	N/A	N/A
Medicare Advantage	No	N/A	N/A
Medicaid	No	N/A	N/A
TRICARE	No	N/A	N/A
VA benefits	No	N/A	N/A
Uninsured (cash pay)	No	N/A	N/A
Commercial insurance, deductible phase	Yes, but card applies after insurance processes claim	Reduces copay to $25	Same

The card works only when insurance covers Zepbound and processes a claim. The card then reduces whatever copay or coinsurance the insurance assigned.

Common misconception: Patients assume the card works like a coupon that applies to cash price. It does not. If your insurance doesn't cover Zepbound, the card provides zero benefit. You pay full cash price.

The 24-month limit:

The savings card expires after 24 months of use or 24 fills, whichever comes first. After that, you pay your plan's full copay or coinsurance. For a patient with 30% coinsurance on a $1,350 medication, that's $405 per month.

Lilly does not offer a renewal or extension program after the 24-month limit. Patients who've used the card for two years and still need Zepbound face a sudden cost increase unless their insurance plan has changed its formulary tier.

What most articles get wrong about "covered" vs "accessible"

Most insurance coverage guides treat "covered" as a binary: yes or no. This is the single largest source of patient frustration.

A plan can cover Zepbound and still make it functionally inaccessible through:

Barrier 1: Step therapy with failure documentation. Your plan covers Zepbound on Tier 3, but only after you've tried and failed phentermine, naltrexone-bupropion, and a 6-month physician-supervised diet program. Each prior medication requires a 90-day trial with documented lack of efficacy. Total delay: 9-12 months before you can even submit a Zepbound PA.

Barrier 2: Specialty pharmacy mandates. Your plan covers Zepbound but requires you to fill it through their designated specialty pharmacy (often Accredo, CVS Specialty, or OptumRx). The specialty pharmacy has a 10-14 day intake process, requires a new patient consultation, and ships on a fixed schedule. Your local pharmacy can't fill it even with an approved PA.

Barrier 3: Quantity limits. Your plan covers Zepbound but limits fills to one pen every 35 days instead of every 28 days. This creates a gap where you run out before your next fill is allowed. The plan classifies the limit as "coverage," not a denial.

Barrier 4: Coinsurance without out-of-pocket maximum credit. Your plan covers Zepbound on specialty tier with 40% coinsurance, but the plan's pharmacy benefit has a separate out-of-pocket maximum from the medical benefit. You pay $540 per month all year, and it never counts toward the $8,000 out-of-pocket max that applies to doctor visits and hospital care.

These barriers are invisible in formulary lookup tools. The tool says "Tier 3, covered." It doesn't mention the six-month step therapy protocol or the specialty pharmacy requirement.

The accurate question is not "Does my insurance cover Zepbound?" It's "Does my insurance provide accessible coverage for Zepbound, and what will I actually pay after all restrictions?"

When your plan denies coverage: the 3-step appeal framework

Approximately 40-45% of Zepbound prior authorization requests are denied on first submission. Denials fall into three categories, each with a different appeal strategy.

Denial type 1: Missing documentation. The PA was denied because the submission didn't include required supporting documents (labs, prior medication trial records, BMI documentation). This is a paperwork denial, not a medical necessity denial.

Appeal strategy: Your provider resubmits with complete documentation. Approval rate on resubmission: 70-80%. Timeline: 3-5 days.

Denial type 2: Step therapy not completed. The plan requires you to try other medications first. You haven't completed those trials yet.

Appeal strategy: If you have a medical contraindication to the required step-therapy medications, your provider submits a step therapy exception request with documentation of the contraindication. Approval rate: 40-50%. If you don't have a contraindication, you must complete the step therapy. No appeal will override this.

Denial type 3: Plan exclusion. Zepbound is not on the plan's formulary at all. The plan categorizes it as "not medically necessary" or "cosmetic."

Appeal strategy:

Step 1: Internal appeal (required first step). Your provider writes a letter of medical necessity citing peer-reviewed evidence, your specific clinical situation, and the plan's coverage policies for similar medications. Include documentation of obesity-related comorbidities (hypertension, dyslipidemia, sleep apnea, NAFLD, joint disease). Timeline: 15-30 days. Approval rate: 15-20%.

Step 2: External review. If internal appeal is denied, you request external review through your state's insurance commissioner. An independent physician reviewer evaluates the case. Timeline: 30-60 days. Approval rate: 20-25%.

Step 3: Employer intervention (if applicable). If you have employer-sponsored insurance, your HR benefits team can sometimes negotiate a formulary exception for individual employees, especially if the employer self-funds the plan. This is not a formal appeal process, but it works in approximately 10-15% of cases where the employee has documented medical need.

The entire appeal process, from first denial to final answer, averages 60-90 days. During this time, patients either pay cash or go without medication.

The compounded tirzepatide alternative

For patients whose insurance doesn't cover Zepbound or whose copay is unaffordable, compounded tirzepatide is the most common alternative.

Pricing comparison:

Option	Monthly cost	Insurance accepted	Savings card eligible
Brand Zepbound (cash)	$1,060-1,350	N/A	No
Brand Zepbound (insured, Tier 3)	$150-450 (typical coinsurance)	Yes	Yes, reduces to $25
FormBlends compounded tirzepatide	$279-399	No	No
Other telehealth compounded tirzepatide	$299-599	No	No

Key differences:

Compounded tirzepatide is not FDA-approved. It's prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription. It's the same active pharmaceutical ingredient (tirzepatide) but not the same product as Zepbound.

Compounded tirzepatide is drawn from a vial using an insulin syringe rather than delivered via Zepbound's auto-injector pen. Patients must be comfortable with manual injection technique.

Compounded tirzepatide is available only while tirzepatide remains on the FDA drug shortage list. If Lilly resolves the shortage, compounding pharmacies lose the legal exemption that allows them to compound a commercially available medication. As of April 2026, tirzepatide remains on the shortage list with no announced resolution date.

When compounded makes sense:

• Your insurance doesn't cover Zepbound
• Your insurance covers Zepbound but your copay exceeds $300/month
• You've exhausted the 24-month savings card limit
• You're on Medicare and need tirzepatide for weight loss (not diabetes)
• You want predictable monthly pricing without PA paperwork

When brand Zepbound makes sense:

• Your insurance covers it with a copay under $100/month
• You qualify for the savings card (reduces to $25/month)
• You prefer FDA-approved medications
• You want the auto-injector pen instead of manual injection
• Your employer's HSA or FSA reimburses only FDA-approved medications

The decision is patient-specific. A licensed provider should review your insurance situation, budget, and clinical needs before recommending either option.

FormBlends clinical pattern: the insurance-to-compounded transition

Across our patient population, we see a consistent pattern in how patients move between brand and compounded tirzepatide based on insurance changes.

Pattern 1: The deductible-phase switch (January-April). Patients with high-deductible plans pay full price for Zepbound in Q1 while meeting their deductible. Many switch to compounded tirzepatide for January through March ($279/month vs $1,350/month), then switch back to brand Zepbound in April when their deductible is met and the savings card reduces copay to $25.

Pattern 2: The job-change gap (any time of year). Patient loses employer coverage, has a 30-60 day gap before new employer coverage starts. Switches to compounded during the gap, then back to brand once new insurance is active.

Pattern 3: The 24-month cliff (month 25 of therapy). Patient has used the Lilly savings card for 24 months. Card expires. Insurance copay jumps from $25 to $405 (30% coinsurance). Patient switches to compounded permanently unless insurance changes formulary tier.

Pattern 4: The Medicare transition (age 65). Patient turns 65, moves from commercial insurance to Medicare Part D. Loses Zepbound coverage entirely. Switches to compounded tirzepatide or, if diabetic, switches to brand Mounjaro (covered for diabetes).

These patterns represent approximately 60% of our compounded tirzepatide patient population. The other 40% start on compounded because they never had insurance coverage to begin with.

The pattern reveals that "insurance coverage" is not a stable state. It changes with employment, age, deductible cycles, and savings card limits. Patients optimizing for cost often switch between brand and compounded multiple times across a multi-year treatment course.

How to verify your specific plan's coverage in 10 minutes

Step 1: Log into your insurance member portal. Every major insurer has one. If you've never logged in, create an account using your member ID from your insurance card.

Step 2: Search the formulary. Look for "Prescription Drug List," "Formulary," or "Drug Coverage" in the portal menu. Search for "Zepbound" or "tirzepatide."

Step 3: Note the tier and restrictions. The formulary will show:

• Tier (2, 3, 4, specialty, or "not covered")
• Prior authorization requirement (yes/no)
• Step therapy requirement (yes/no)
• Quantity limits

Step 4: Call the pharmacy benefits number on the back of your insurance card. Ask three specific questions:

1. "What is the prior authorization approval rate for Zepbound for weight management?"
2. "What is the typical approval timeline?"
3. "Does my plan require step therapy, and if so, which medications must I try first?"

Step 5: Run a test claim at your pharmacy. Bring your insurance card to any pharmacy. Ask the pharmacist to run a "test claim" or "adjudication" for Zepbound without actually filling the prescription. This returns your exact copay or coinsurance amount. It's free and takes 2-3 minutes.

Step 6: Download the Lilly savings card (if you have commercial insurance). Go to Zepbound.com, click "Savings & Support," download the card. Bring it to the pharmacy alongside your insurance card when you fill.

This 10-minute process gives you three critical pieces of information: whether your plan covers Zepbound, what you'll pay, and whether the savings card will work for you.

FAQ

Which insurance companies cover Zepbound? Most major commercial insurers cover Zepbound with prior authorization, including UnitedHealthcare, Aetna, Cigna, Blue Cross Blue Shield, Anthem, Humana, and Kaiser Permanente. Coverage varies by specific plan. Approximately 60-65% of commercial plans include Zepbound on their formulary as of 2026.

Does Medicare cover Zepbound? No. Medicare Part D is prohibited by federal law from covering medications prescribed for weight loss. Medicare Advantage plans may offer limited supplemental coverage, but fewer than 5% of plans do. Medicare patients pay cash ($1,060-1,350/month) or use compounded tirzepatide.

Does Medicaid cover Zepbound? It depends on your state. Eighteen states cover GLP-1 medications for obesity without requiring diabetes. Thirty-two states cover GLP-1s only for diabetes. Check your state Medicaid formulary or call your Medicaid managed care plan.

How much does Zepbound cost with insurance? Typical cost with commercial insurance ranges from $25/month (with savings card) to $500/month (specialty tier coinsurance without savings card). The exact amount depends on your formulary tier, deductible status, and whether you qualify for the Lilly savings card.

Does the Zepbound savings card work with Medicare? No. The Lilly savings card explicitly excludes Medicare, Medicaid, TRICARE, and all government-funded insurance programs. It works only with commercial insurance that covers Zepbound.

What is prior authorization for Zepbound? Prior authorization is a requirement that your doctor submit clinical documentation to your insurance company proving Zepbound is medically necessary before the plan will cover it. Typical criteria include BMI ≥30, attempted lifestyle modification, and sometimes failure of other weight-loss medications first.

How long does Zepbound prior authorization take? Average approval time is 5-10 days for plans with streamlined processes, 10-21 days for plans with more complex review. Denials often take longer (14-21 days) because they sit until the review deadline. Resubmissions after denial add another 7-14 days.

Can I appeal if my insurance denies Zepbound? Yes. You can file an internal appeal (15-30 day process), then an external review through your state insurance commissioner (30-60 days). Approval rates are approximately 15-20% for internal appeals and 20-25% for external reviews.

Does Blue Cross Blue Shield cover Zepbound? Blue Cross Blue Shield operates as independent state-level companies with different formularies. Most BCBS plans cover Zepbound on Tier 2 or Tier 3 with prior authorization, but coverage varies by state and specific plan type (employer vs marketplace vs individual).

Is compounded tirzepatide covered by insurance? No. Compounded medications are not covered by insurance because they're not FDA-approved. Compounded tirzepatide is a cash-pay option, typically $279-599/month depending on provider. It's an alternative for patients whose insurance doesn't cover Zepbound or whose copay is unaffordable.

What happens when the Zepbound savings card expires? The savings card expires after 24 months or 24 fills. After expiration, you pay your insurance plan's full copay or coinsurance with no reduction. For patients with 30% coinsurance, this often means a jump from $25/month to $400+/month. Lilly does not offer card renewal.

Does TRICARE cover Zepbound? TRICARE covers Zepbound for weight management with prior authorization, but beneficiaries do not qualify for the Lilly savings card. Typical TRICARE copay is $33 for a 90-day supply at military pharmacies, $68 for a 90-day supply at retail network pharmacies.

Sources

1. Eli Lilly and Company. Zepbound Prescribing Information. 2024.
2. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6. 2023.
3. Kyle TK et al. Obesity coverage gap in Medicare Part D. Obesity. 2024.
4. National Association of Medicaid Directors. State Medicaid Coverage of Anti-Obesity Medications Survey. 2026.
5. GoodRx Research Team. Prior Authorization Approval Rates for GLP-1 Medications. 2025.
6. Lilly USA. Zepbound Savings Card Terms and Conditions. 2024.
7. American Medical Association. Prior Authorization Physician Survey. 2024.
8. Kaiser Family Foundation. Medicare Advantage Supplemental Benefits Analysis. 2025.
9. Academy of Managed Care Pharmacy. Formulary Tier Placement Trends 2024-2026. 2025.
10. U.S. Food and Drug Administration. Drug Shortages Database (Tirzepatide). Updated April 2026.
11. Blue Cross Blue Shield Association. Medical Policy: Anti-Obesity Pharmacotherapy. 2025.
12. National Conference of State Legislatures. State Legislation on GLP-1 Coverage. Updated March 2026.
13. Avalere Health. Commercial Insurance Coverage of Obesity Medications Report. 2025.
14. UnitedHealthcare. Clinical Pharmacy Program: GLP-1 Receptor Agonists. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and Trulicity are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Medicare, Medicaid, and TRICARE are U.S. government programs. UnitedHealthcare, Aetna, Cigna, Blue Cross Blue Shield, Anthem, Humana, and Kaiser Permanente are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.